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Abstract
Objective: We aimed to determine the physiological and hemodynamic changes in patients who
were undergoing hyperthermic intraperitoneal chemotherapy (HIPEC) cytoreductive surgeries.
Methods: This prospective, observational study enrolled 21 patients who were undergoing
elective cytoreductive surgery with HIPEC at our hospital over 2 years. We collected vital
signs, hemodynamic parameters including global end-diastolic volume index (GEVI) and extravas-
cular lung water index (ELWI) using the VolumeViewTM system, and arterial blood gas analysis
from all patients. Data were recorded before skin incision (T1); 30 minutes before HIPEC initi-
ation (T2); 30 (T3), 60 (T4), and 90 (T5) minutes after HIPEC initiation; 30 minutes after HIPEC
completion (T6); and 10 minutes before surgery completion (T7).
Results: Patients showed an increase in body temperature and cardiac index and a decrease in
the systemic vascular resistance index. GEDI was 715.4 (T1) to 809.7 (T6), and ELWI was 6.9
(T1) to 7.3 (T5).
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Conclusions: HIPEC increased patients’ body temperature and cardiac output and decreased
systemic vascular resistance. Although parameters that were extracted from the VolumeViewTM
system were within their normal ranges, transpulmonary thermodilution approach is helpful in
intraoperative hemodynamic management during open abdominal cytoreductive surgery with
HIPEC.
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Introduction
Peritoneal carcinomatosis involves the
spread of a tumor over the peritoneal sur-
face secondary to the seeding of gynecologic
and non-gynecologic tumors in the perito-
neum. It is difficult to treat, and treatment
outcomes are poor.1,2 Recently, cytoreduc-
tive surgery with hyperthermic intraperito-
neal chemotherapy (HIPEC) has been
reported to be an effective treatment
approach for peritoneal cancer, and several
studies have demonstrated a significantly
enhanced survival rate with this treatment
approach.3–6 HIPEC involves the direct
administration of highly concentrated anti-
cancer agents into the tumor tissue via a
glucose carrier solution at high temperature.
This stresses the cardiovascular system,
resulting in an increase in the heart rate
(HR), cardiac index (CI), and oxygen con-
sumption and a decrease in the systemic vas-
cular resistance index (SVRI).7–9 Therefore,
the continuous monitoring of arterial blood
pressure and central venous pressure (CVP)
is important, and in certain cases, vasopres-
sors and inotropic agents are recommended
to maintain the blood pressure.10
In addition, appropriate fluid manage-
ment and the maintenance of urinary
output are critical because massive fluid
shifts and circulating intravascular volume
loss frequently occur during surgery.11–13
The wide extent of surgical resection and
physicochemical trauma, as well as
HIPEC, alters capillary permeability,
resulting in tissue damage and facilitating
abdominal and systemic complications,
with postoperative morbidity and mortality
rates ranging from 22% to 41% and 2% to
5%, respectively.14,15 However, there is
insufficient information available from pre-
viously published studies on the anticipated
metabolic and physiologic derangement for
anesthesiologists. The VolumeViewTM
system (Edwards Lifesciences), which uses
a novel algorithm for the mathematical
analysis of the thermodilution curve,16 has
been recently introduced. Precise physiolog-
ical parameters, such as the global
end-diastolic volume index (GEDI), extra-
vascular lung water index (ELWI), and pul-
monary vascular permeability index
(PVPI), can be derived from the dilution
curve. Therefore, this system can provide
more precise information for hemodynamic
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alteration during major abdominal surgery
and assists in the management of fluid
supply to high-risk patients with issues
between fluid restriction and overloading.
The present study aimed to investigate
the physiological changes, including the
new transpulmonary thermodilution
approach with the VolumeViewTM system,
in patients who are undergoing cytoreduc-
tive surgery with HIPEC.
Methods
Patients
This was a single-center, prospective, obser-
vational study. The study protocol was
approved in accordance with the ethical
standards of the Severance Hospital
Research Ethics Committee and
Institutional Review Board (IRB number:
4-2014-0854). Additionally, the study was
registered at ClinicalTrials.gov
(NCT02325648). This study was conducted
in accordance with the World Medical
Association Declaration of Helsinki.
Furthermore, the submitted manuscript
conforms to the ICMJE Recommendations
for the Conduct, Reporting, Editing, and
Publication of Scholarly Work in Medical
Journals. All patients provided written
informed consent before they were enrolled
into the study, which occurred when the
patients were informed of the study objec-
tives and methods 1 day before the surgery.
Adult patients who were undergoing elective
cytoreductive surgery with HIPEC at our
hospital between December 2014 and April
2016, were assessed for eligibility. The exclu-
sion criteria were a sudden change in the sur-
gical plan and the retraction of consent.
Anesthesia
Upon arrival in the operating room, routine
monitoring was started, including electro-
cardiography, pulse oximetry, noninvasive
blood pressure monitoring, and capnogra-
phy. Anesthetic depth was monitored using
a bispectral index (BIS) monitor (Aspect A-
2000TM, Aspect Medical System Inc.,
Newton, MA, USA). Anesthesia induction
occurred through a bolus administration of
1.5 to 2 mg/kg of propofol and 1 to 2 mg/kg
of remifentanil. Anesthesia was maintained
using 4% to 7% desflurane with an adjuvant
intravenous (IV) infusion of 0.05 to 0.2 mg/
kg/minute of remifentanil. Rocuronium,
which is a neuromuscular relaxing agent,
was injected at 0.6 mg/kg to facilitate trache-
al intubation in all patients. Tracheal intu-
bation was performed in female and male
patients using a 6.5-mm and 7.5-mm (inter-
nal diameter) tracheal tube, respectively.
The cuff pressure of the tracheal tube was
maintained at 20 to 25 cm H2O throughout
the procedure. Mechanical ventilation was
maintained with a tidal volume of 8mL/kg
of ideal body weight, and the ventilatory fre-
quency was adjusted to maintain an end-
tidal CO2 concentration of 35 to 45 mmHg
with an air/oxygen mixture (fraction of
inspired oxygen, 0.5). BIS scores were main-
tained in the range of 40 and 60, and the
mean arterial pressure was maintained
within 20% of the pre-induction value. In
all patients, a central venous catheter was
inserted for additional venous access and
hemodynamic monitoring.
HIPEC procedure
All patients underwent cytoreductive sur-
gery followed by HIPEC. For HIPEC, the
open abdomen technique was used, allow-
ing surgeons to manipulate abdominal con-
tents. Inflow and outflow tubes were
connected to a hyperthermia pump.
Preheated 5% glucose peritoneal dialysis
solution (1000mL/minute) was circulated
through the abdominal cavity. When the
target temperature of 41C to 42C was
reached, chemotherapeutic agents were
added to this solution. HIPEC was
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scheduled for 90 minutes. The perfusate
was then drained and the abdominal
cavity was washed out with 4000mL of
normal saline.
Measurements
A VolumeViewTM catheter (Edwards
Lifesciences, Irvine, CA, USA) was inserted
into the left or right femoral artery and con-
nected to the EV 1000 monitoring system
(Edwards Lifesciences). Thermodilution
measurements were performed in sets of at
least three consecutive injections of 15 to
20mL cold saline, which were randomly
distributed over the respiratory cycle. All
hemodynamic data were electronically
recorded at 100 Hz internally in the EV
1000 system and downloaded for analysis.
Hemodynamic parameters, such as CI,
stroke volume index (SVI), SVRI, and
stroke volume variation (SVV), were con-
tinuously measured using the EV 1000
monitor, and new additional hemodynamic
data, such as the GEDI, ELWI, and PVPI,
were extracted. These volumetric parame-
ters were calibrated and obtained when
cold saline was infused to perform the ther-
modilution measurements. In addition, we
defined the following seven time points:
before skin incision (T1); 30 minutes
before HIPEC (T2); 30 (T3), 60 (T4), and
90 (T5) minutes after HIPEC initiation; 30
minutes after HIPEC completion (T6); and
10 minutes before surgery completion (T7),
to describe the course of the intervention.
Laboratory test results and arterial blood
gas analysis (ABGA) results were also
recorded.
Fluid resuscitation
The amount of serious intravascular
volume loss during surgery was estimated
by the investigator and was equally
substituted with additional crystalloid infu-
sion. We recorded the detectable amount of
blood loss in the suction unit during surgery
but did not estimate the blood that was
absorbed in the abdominal compresses.
An isotonic HES preparation (VolulyteVR ,
Fresenius Kabi AG, Bad Homburg,
Germany) was administered to compensate
for blood loss. The transfusion of red cell
concentrates was considered when the
hemoglobin level decreased below 8 g/dL.
A continuous infusion of vasopressor was
routinely used to maintain the mean arterial
pressure at not more than 20% below the
baseline value during surgery. All patients
received a transurethral urine catheter, and
urine output was measured hourly.
Diuretics were not used during surgery.
Body temperature control
Body temperature was continuously mea-
sured with a thermodilution prove in the
VolumeViewTM catheter. Patients were
warmed with a BairHggerTM upper body
airstream blanket (3M GmbH, Neuss,
Germany), hot line, and heated circuit
during cytoreductive surgery. Patients
were cooled with a BairHggerTM upper
body airstream blanket (3M GmbH) and
cold IV fluids to maintain normal body
temperature during HIPEC.
Postoperative data
We collected postoperative patient data,
including coagulation profiles (platelet
count, prothrombin time, and partial
thromboplastin time), serum albumin
levels, renal function profiles, respiratory
function restoration, bowel movement
recovery, complications, and the length of
intensive care unit (ICU) and hospital stays.
We elucidated the occurrence of acute
kidney injury (AKI) in accordance with
the RIFLE (Risk, Injury, Failure, Loss,
and End-stage Kidney Disease [ESKD]) cri-
teria. The criteria are based on an elevated
serum creatinine level and decreased
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estimated glomerular filtration rate and uri-
nary output compared with baseline, and
they have been used to define AKI and clas-
sify patients on the basis of the AKI sever-
ity.17 Bowel movement recovery was
evaluated on the basis of the gas passing
time, sips of water time, and soft diet
time. Postoperative complications included
surgical complications that required re-
operation during the hospital stays, and
non-surgical complications that required
conservative care.
Statistical analysis
Descriptive analyses were performed to
demonstrate patient characteristics.
Continuous variables are reported as the
mean (standard deviation or range), and
categorical variables are reported as the
number of subjects (percentage). All
descriptive statistics were obtained using




Among 31 patients who were scheduled to
undergo cytoreductive surgery with HIPEC,
22 patients who provided consent were
enrolled between November 2014 and
April 2016. Among these 22 patients, one
patient was excluded because of a change
in the surgical plan. The remaining 21
patients were included in the analysis.
Table 1 presents the patient demographic
data. The average age of the patients was
59.0 11.7 years, and there were 13 men
and eight women who were included in the
analysis. Colon cancer was the most
common cause of peritoneal cancer in our
study population. The other causes included
appendix cancers, sigmoid cancers, and
rectal cancers. The departments of
Hepatobiliary and Pancreas Surgery and
Urologic Surgery cooperated for the colo-
rectal surgery.
Intraoperative management
The anesthetic duration was nearly 12 hours.
For postoperative pain control, 17 patients
received IV patient-controlled analgesia
(PCA) and the remaining four patients
received epidural PCA. Fluid was adminis-
tered with total crystalloid at 6983.3mL and
total colloid at 1177.2mL. The urine output
was maintained at 122mL/hour, and the
estimated blood loss (EBL) was 780mL.
To decrease the glucose level, rapid insulin
(6.8 IU) was administered IV. In most
patients (20/21), vasopressors were used,
Table 1. Patient characteristics.
Characteristic N¼ 21




Cancer origin (n, %)
Colon 6 (28.6)
Appendix 6 (28.6)
Sigmoid colon 4 (19)
Rectum 4 (19)
Others 1 (4.8)
Height (cm) 162.1 (8.5)
Weight (kg) 54.5 (9.5)








Urologic surgery 6 (28.6)
Upper gastrointestinal surgery 4 (19.0)
Gynecologic surgery 3 (14.2)
Vascular surgery 1 (4.7)
Thoracic surgery 1 (4.7)
Data are presented as the mean (standard deviation) or
number (percentage).
ASA, American Society of Anesthesiologists.
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Table 3 presents the various intraoperative
parameters, including physiological
changes. During the HIPEC 90-minute
period, hyperthermia occurred with a
mean overall peak body temperature of
38.0C. The mean blood pressure decreased
to 76 mmHg and HR increased to 95 bpm
until HIPEC completion. Additionally, the
CI increased to 3.8, SVI increased to 5.2,
and SVV increased to 11.4 during HIPEC.
Their peak levels did not occur at the same
time point. In advanced hemodynamic
monitoring, the ELWI, PVPI, and GEDI
increased overall during HIPEC and
changed significantly over time. The SVRI
decreased to 1326.8, and it remained low
until the end of surgery. In accordance
with ABGA, the serum lactate level
increased by four-times compared with the
initial baseline level, and the serum glucose
level increased by 2.5-times compared with
the initial level.
Postoperative recovery profile
For postoperative coagulation profiles
(Table 4), the platelet count, prothrombin
time, and partial thromboplastin time
decreased compared with the preoperative
levels. Additionally, the albumin level
decreased after surgery. One patient experi-
enced an acute deterioration of renal func-
tion in accordance with the RIFLE criteria
during the hospital stay. Nine ICU patients
received ventilation, and six patients were
maintained with vasopressors upon ICU
arrival. Three cases of postoperative com-
plications, including adhesion, bleeding,
and wound dehiscence, needed surgical
treatments, while four patients with
Table 2. Intraoperative parameters.
Intraoperative parameter
Surgical time (minutes) 638.8 (207.8)





Crystalloid (mL) 6983.3 (4496.4)
Hydroxyethyl starch 6% (mL) 976.2 (460.3)
Packed RBC (mL) 207.1 (378.2, 0–1400)
Fresh-frozen plasma (mL) 71.4 (181.4, 0–600)
Albumin (mL) 109.5 (151.3, 0–500)
Output
Urine output (mL) 1464.8 (898.0)
Estimated blood loss (mL) 780.0 (928.6, 50–3350)
Rapid insulin (unit) 6.8 (4.3)
Vasopressor
Ephedrine (n, %) 14/21 (66.7)
Phenylephrine (n, %) 15/21 (71.4)
Norepinephrine (n, %) 2/21 (9.5)
Data are presented as the mean (standard deviation, range) or number (percentage).
RBC, red blood cell.
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complications, including pancytopenia,
pneumonia, and pancreas fistula, needed
conservative treatments. The mean length
of hospital stay was 18.5 days, and the
mean length of ICU stay was 1.4 days.
Two patients died within the study period
(18 months).
Discussion
In our study, we prospectively described the
physiological changes during open abdom-
inal cytoreductive surgery with HIPEC. To
the best of our knowledge, the present study
is the first trial to examine the cardiopulmo-
nary and intravascular volume status with a
new thermodilution measurement approach
using the VolumeViewTM system in cytore-
ductive surgery with HIPEC.
A previous systemic review of patients
with pseudomyxoma peritonei that was
treated with cytoreductive surgery and
HIPEC demonstrated that the median sur-
vival duration ranged from 51 to 156
months and that the 5-year survival rate
ranged from 52% to 96% depending on
the disease severity at the time of treat-
ment.18,19 In addition, Verwaal et al.20
Table 4. Postoperative recovery profiles.
Postoperative parameter
Coagulation profile
Preoperative platelet count (/mL) 307,048 (127,403)
Postoperative platelet count (/mL) 238,952 (104,884)
Preoperative PT (INR) 1.02 (.10), 94.4 (8.4)
Postoperative PT (INR) 1.27 (.29), 76.0 (14.4)
Preoperative pTT (s) 32.6 (9.0)
Postoperative pTT (s) 34.1 (8.2)
Preoperative albumin (g/dL) 3.9 (.6)
Postoperative albumin (g/dL) 2.4 (.6)
Acute kidney injury (n, %) 1 (4.8)
Respiration
Extubation in the ICU (n, %) 9 (42.9)
Postoperative extubation (time) 9.9 (26.7, 0–124)
Vasopressor maintenance (n, %) 6 (28.6)
Bowel movement
SOW (hours) 66.3 (29.7)
GPT (hours) 144.8 (115.5)
SDT (hours) 129.5 (117.3)




ICU admission (n, %) 17/21 (81)
ICU LOS (day) 1.4 (1.3)
POD LOS (day) 18.5 (10.2)
*Mortality (n, %) 2/21 (9.5)
Data are presented as the mean (standard deviation, range) or number (percentage).
*Death during the study period.
PT, prothrombin time; INR, international normalized ratio; pTT, partial thromboplastin time; ICU,
intensive care unit; SOW, sips of water; GPT, gas passing time; SDT, soft diet time; LOS, length of stay;
POD, postoperative day.
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reported that patients with peritoneal carci-
nomatosis secondary to colorectal cancer
treated with cytoreductive surgery and
HIPEC showed a significant increase in
the median survival (22 months) compared
with survival in patients who were treated
with systemic chemotherapy alone (12
months). Consequently, cytoreductive sur-
gery with HIPEC is currently recognized
as the standard of care for managing peri-
toneal carcinomatosis secondary to colorec-
tal or gynecological cancers in selected
patients.8,21,22
Despite continuous improvements in sur-
gical and anesthetic techniques, cytoreduc-
tive surgery with HIPEC is often associated
with disturbances in hemodynamics, coagu-
lation, respiratory exchange, and nutri-
tion.7,23 Therefore, understanding the
pathophysiological changes accompanying
this procedure is crucial and helpful for
patients who are undergoing anesthesia.
There were three studies that systemically
evaluated additional hemodynamic param-
eters, such as cardiac output and vascular
resistance, which were assessed using either
esophageal Doppler or transpulmonary
thermodilution (TPTD) and pulse contour
analysis.24,25 Although the results of the
variation in systemic vascular resistance
and cardiac output were not consistent
and significant,26 a decrease in the SVRI
and an increase in the CI were only mea-
sured in patients during the HIPEC open
coliseum technique,27 which is consistent
with our results.
Considering the duration of surgery,
large fluid shifts, frequent requirement for
vasopressor support, and intraoperative
hemodynamic changes need constant and
adequate attention, although they are tran-
sient in nature. The intraoperative monitor-
ing of hemodynamics is multipronged, and
across studies on cytoreductive surgery with
HIPEC, the monitoring approaches that
were used included at least a CVP line, inva-
sive arterial pressure monitoring line, and
hourly urine output assessment.28,29
However, the CVP and amount of urine
are not accurate indices of fluid responsive-
ness, and they only help to detect a patient’s
intravascular volume status.30–32 In addi-
tion, both the pulse pressure variation and
SVV, which may exhibit faster responses to
sudden changes in volume responsiveness,
are calculated using an arterial pressure
waveform analysis method. However, some
studies have reported clinically unacceptable
accuracy for these systems in patients with
vasodilation or impaired systolic function
during a hypovolemic state.33,34
To overcome these challenges, a new
TPTD system was recently developed and
introduced into clinical practice. It involves
a specific thermistor-tipped arterial cathe-
ter, the VolumeViewTM catheter, and the
EV 1000 monitoring platform, and it uses
a novel algorithm to mathematically ana-
lyze the thermodilution curve.16 After
injecting a cold indicator into the superior
vena cava, TPTD allows the computation
of cardiac output from a TPTD curve that
was recorded using a thermistor-tipped
femoral arterial catheter.35 Volumetric pre-
load indicators, such as the GEDI,36–38
have been shown to be the reliable indica-
tors of cardiac preload and have been suc-
cessfully implemented in therapeutic
strategies that may improve outcomes.
The GEDI ranged from 715.4 to 809.7 in
the present study, and this level steadily
increased during the HIPEC period because
of fluid resuscitation for compensating a
decreased SVRI and increased SVV and
HR. The ELWI, which is measured with
single indicator dilution, is a reliable mea-
sure of pulmonary edema that has been val-
idated against postmortem gravimetric
measurement in animals.39–41 Moreover,
ELWI and PVPI may be used as criteria
to indicate the risk of fluid administra-
tion.42 In particular, ELWI 10mL/kg
was defined as pulmonary edema, although
no definitive quantitative criteria for ELWI
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that are associated with pulmonary edema
have been established. A previous human
autopsy study reported that the normal
ELWI value is approximately 7.4 (SD 3.3)
mL/kg, and this value can distinguish
between healthy and pathological lungs.43
Because ELWI ranged from 6.9 to 7.3
(peak value during HIPEC) in our study,
the risk of intraoperative pulmonary
edema occurring that is related to the cytor-
eductive surgery with HIPEC was lower
than anticipated. However, HIPEC would
be a factor that interfered with the measure-
ment of volumetric parameters.
During HIPEC, the circulation support
with inotropes/vasopressors does not have
definite recommendations.30 The common
practice in the setting of vasodilation was
the use of noradrenaline and methoxamine,
and it usually depends on institutional pro-
tocols. We almost selected and administered
phenylephrine to our patients as a vasopres-
sor because of increased HR and decreased
SVRI. As a compensatory mechanism for
the lower SVRI, increased cardiac output
and HR were measured using VigileoTM
during HIPEC, which is consistent with pre-
vious reports.44,45 The SVRI remained low
during HIPEC and postoperatively. In six
patients, the vasopressor was maintained
when they left the operating room.
The choice of intraoperative fluid infu-
sion involves balanced infusion therapy to
maintain the preload, colloid oncotic pres-
sure, end-organ perfusion (urinary output),
and electrolyte homeostasis.10 To prevent
hemodynamic imbalance and reductions in
end-organ perfusion, the anesthesiologist’s
main aim should be adequate fluid replace-
ment, blood loss adjustment, and mainte-
nance of euvolemia. Moreover, in surgery
with HIPEC, AKI usually occurs because
of a decrease in blood pressure and insuffi-
ciency of intravascular volume. With main-
tenance of normovolemia only and
adequate urine output, no change in creat-
inine values occurred during cytoreductive
surgery and HIPEC,12,46 and in our study,
only one patient experienced AKI. It would
be helpful to perform a comprehensive eval-
uation of a patient’s intravascular volume
status with closed monitoring involving
various approaches, including the use of
the VolumeViewTM system.7
The severity of metabolic changes that
were observed during HIPEC depends on
the type of carrier solution and degree of
hyperthermia. The carrier solution that
was used in this study was a fluid contain-
ing 5% dextrose. Metabolic changes occur
when both glucose and free water are
absorbed into the plasma causing hypergly-
cemia and dilutional hyponatremia.1 In our
study, body temperature increased to 38C
for 2 hours during the HIPEC period.
Hyperthermia has been shown to increase
metabolic activity, HR, carbon dioxide pro-
duction, and ultimately oxygen consump-
tion.7 Additionally, a previous study
reported increases in the lactate level of 2
to 4 mmol/L.47 Although the results of this
study also showed elevated levels of glucose
and lactic acid, the levels of electrolytes,
such as sodium, were almost in the normal
range. This result may be associated with
closed monitoring and adequate fluid man-
agement, which is made possible by the new
TPTD system.
After HIPEC, patients are often admit-
ted to the ICU or are kept in the post-
anesthesia care unit to monitor their
organ function, manage intraoperative
complications, and correct coagulopathy.
Physiological perturbations during the peri-
operative period affect the duration of their
ICU stay and may precipitate multisystem
organ failure.1 Although the length of ICU
stay (1.4 days) in our study was similar to
the length that was reported in other stud-
ies, postoperative complications after sur-
gery were unavoidable in our study. For
postoperative outcomes, there are many
debates about the ideal postoperative nutri-
tion strategies. A retrospective study by
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Arakelian et al.48 showed that postopera-
tive ileus is a common problem after sur-
gery. Although there are no prospective
studies, most patients were able to tolerate
oral feeding between 7 and 11 days after
surgery. To promote healing and improve
intestinal transit, early enteral feeding is
both safe and beneficial for patients.49–51
In our study, the recovery time for bowel
movement was about 6 days, and the water
and soft diet feeding times were shorter
than the gas passing time.
Some limitations must be acknowledged.
This was a prospective observational study,
and the number of enrolled patients was rel-
atively low. Consequently, the results of our
study may not be generalizable. In addition,
it may be more critical to investigate the
course of pathophysiologic changes, includ-
ing fluid redistribution, after HIPEC surgery
compared with intraoperative conditions.
However, our findings will be a valuable
source of information for further studies
that address anesthetic management of
patients who are scheduled to undergo
major surgery that is accompanied by
severe hemodynamic changes, such as
those associated with HIPEC.
In conclusion, our study demonstrated
various physiological changes via the devel-
oped hemodynamic monitoring system in
patients who underwent open cytoreductive
abdominal surgery with HIPEC. Fluid ther-
apy remains one of the most challenging
issues for the anesthesia team. Therefore,
anesthesiologists should constantly explore
the most optimal intraoperative anesthetic
management, including the maintenance of
intravascular volume status, in major sur-
gery that is expected to result in acute
hemodynamic changes.
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